All Articles

The concept of staging is inherently important to all patients and all who practice clinical medicine; the T(umor) N(ode) M(etastasis) System is an important strategy for classifying adult solid tumors.

Quick action and an immediate referral addressed a life-threatening complication.

In 2023, much research has been conducted on the treatment of biliary tract cancer (BTC), with an emphasis on novel targeted therapies and combination strategies. Important advances in treatment for patients with BTC were presented at society conferences such as the American Society of Clinical Oncology (ASCO), ASCO GI, and European Society for Medical Oncology.

In the KEYNOTE-966 study, pembrolizumab was added to gemcitabine/cisplatin to assess outcomes in patients with advanced biliary tract cancer.

This post-hoc analysis of the ABC-01, -02, and -03 clinical trials provides reference survival data for patients with advanced extrahepatic cholangiocarcinoma treated with first-line gemcitabine/cisplatin chemotherapy.

Investigators pooled data from 3 trials to evaluate tinengotinib in patients with advanced, refractory/relapsed cholangiocarcinoma who previously received an FGFR inhibitor.

Researchers evaluated KLF5 expression and its inhibition in cholangiocarcinoma using clustered regularly interspaced short palindromic repeats technology.

In this ongoing phase 2 study, the efficacy of SHR-1316 plus IBI310 is being evaluated in patients with advanced intrahepatic cholangiocarcinoma after inadequate response to first-line therapy.

Dr Mahmood presented results from the largest multi-institutional review of efficacy outcomes following targeted agents in patients with cholangiocarcinoma.

In the phase 2 component of the phase 2/3 BEER-BTC study, bevacizumab plus erlotinib improved outcomes in patients with advanced biliary tract cancers.